Literature DB >> 2018362

Synthesis, mutagenicity, binding to pBR 322 DNA and antitumour activity of platinum(II) complexes with ethambutol.

M Coluccia1, F P Fanizzi, G Giannini, D Giordano, F P Intini, G Lacidogna, F Loseto, M A Mariggio, A Nassi, G Natile.   

Abstract

Platinum complexes with N,N'-bis(1-hydroxybut-2-yl)ethylenediamine, [PtCl2(ethambutol)] were prepared and the biological activity of three isomers [with (-), (+) and (+/-) ethambutol, respectively] investigated. All species interact with the Bam HI and Ava I recognition sequences showing a binding preference for GC rich sequences of DNA. The complex which showed the greatest interaction with adjacent guanines, [PtCl2[+/-)ethambutol)] was also found to be the most mutagenic of the three. On the other hand, only [PtCl2[+)ethambutol)] had a considerable antitumour activity against both P388 leukaemia and Lewis lung carcinoma, and this was not correlated either with restriction enzyme blocking activity or with mutagenicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2018362

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Synthesis, characterization, and biological activity of platinum II, III, and IV pivaloamidine complexes.

Authors:  Marilù Sinisi; Valentina Gandin; Teresa Saltarella; Francesco P Intini; Concetta Pacifico; Christine Marzano; Giovanni Natile
Journal:  J Biol Inorg Chem       Date:  2014-05-22       Impact factor: 3.358

2.  DNA interactions of antitumor cisplatin analogs containing enantiomeric amine ligands.

Authors:  J Malina; C Hofr; L Maresca; G Natile; V Brabec
Journal:  Biophys J       Date:  2000-04       Impact factor: 4.033

3.  Good response of malignant pleural effusion from carcinoma of unknown primary site to the anti-tuberculosis therapy: a case report.

Authors:  Qihua Gu; Chengping Hu; Jingjing Qu
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

4.  Solution behaviour and biological activity of bisamidine complexes of platinum(II).

Authors:  C Marzano; S Mazzega Sbovata; F Bettio; R A Michelin; R Seraglia; T Kiss; A Venzo; R Bertani
Journal:  J Biol Inorg Chem       Date:  2007-01-09       Impact factor: 3.862

Review 5.  Chiral discrimination in platinum anticancer drugs.

Authors:  Michele Benedetti; Jaroslav Malina; Jana Kasparkova; Viktor Brabec; Giovanni Natile
Journal:  Environ Health Perspect       Date:  2002-10       Impact factor: 9.031

6.  Synthesis, Characterization, and Antiproliferative Activity of Novel Chiral [QuinoxP*AuCl2]+ Complexes.

Authors:  Adedamola S Arojojoye; R Tyler Mertens; Samuel Ofori; Sean R Parkin; Samuel G Awuah
Journal:  Molecules       Date:  2020-12-04       Impact factor: 4.411

7.  The biological activity of cisplatin and dibromodulcitol in combination therapy.

Authors:  A Jeney; I Kovalszky; E Rásó; R E Durand; J Fürész; K Lapis
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.